drugset / Trial / NCT02608684
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
Timeline
- Start
- 2016-02-08
- Primary completion
- 2019-05-17
- Completion
- 2022-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 750 mg/m2 | Intravenous |